The White House announced nine additional most-favored-nation (MFN) prescription pricing agreements with midsized and large biopharma companies, expanding coverage to Medicaid and reducing prices to levels available in peer nations. The agreements bring the total number of participating manufacturers to 26, covering 89% of the branded drug market, and include commitments tied to U.S. manufacturing and drug supply initiatives.